Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfm615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Phosphate-Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers.
Clin Transl Sci
January 2025
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Despite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end-stage kidney disease on dialysis. Characteristics of currently available phosphate binders that lead to poor patient experiences such as large drug volume size of required daily medication (e.g.
View Article and Find Full Text PDFConstructing an electrochemical sensor with screen-printed electrodes incorporating TiCT-PDA-AgNPs for lactate detection in sweat.
Talanta
December 2024
Institute of Chemical Biology and Nanomedicine (ICBN), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, China. Electronic address:
Sweat lactate levels are closely related to an individual's physiological state and serve as critical indicators for assessing exercise intensity, muscle fatigue, and certain pathological conditions. Screen-printed electrodes (SPEs) offer a promising avenue for the development of low-cost, high-performance wearable devices for electrochemical sweat analysis. The material composition of SPEs significantly impacts their detection sensitivity and stability.
View Article and Find Full Text PDFEfficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients.
Int Urol Nephrol
December 2024
Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Background: Hyperphosphatemia is common in chronic kidney disease (CKD) patients, especially patients on hemodialysis. Tenapanor is a novel drug with fewer side effects and high compliance compared to traditional phosphate binders. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of tenapanor.
View Article and Find Full Text PDFEffectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies.
Nefrologia (Engl Ed)
December 2024
Department of Medical Doctor Study Program, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia.
Background: Chronic kidney disease (CKD) is a major global health problem. Hyperphosphatemia is frequent in CKD and a reason for increased morbidity and mortality as it generates hyperparathyroidism, high fibroblast growth factor 23 (FGF23), and hypocalcemia. Available hyperphosphatemia therapies still have limitations, including risk of metal overload, cardiovascular calcification, and systemic adverse effects (AEs).
View Article and Find Full Text PDFA randomized pilot study to evaluate the stability, taste, and palatability of a novel liquid formulation of tenapanor.
Drug Dev Ind Pharm
December 2024
Quotient Sciences, Nottingham, UK.
Objective: This pilot study aimed to develop a liquid formulation of tenapanor and evaluate taste and palatability with different sweetener and flavor combinations.
Significance: Tenapanor is a first-in-class, minimally absorbed, small molecule inhibitor of intestinal sodium/hydrogen exchanger 3, indicated (as tablets) to treat adults with constipation-predominant irritable bowel syndrome. It is also approved as add-on therapy to reduce serum phosphorus in adults with chronic kidney disease on dialysis who are intolerant of, or unacceptably responsive to, any dose of phosphate binder therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!